Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bernard Klein

Showing results (41-50 of 121) with videos related to

Pageof 13
Sort By:
British Journal of Haematology|April 17, 2004
The Bcl-2 family member Bfl-1/A1 is strongly repressed in normal and malignant plasma cells but is a potent anti-apoptotic factor for myeloma cellsKarin Tarte, Michel Jourdan, Jean Luc Veyrune, et al.
Molecular Cancer Therapeutics|October 23, 2012
Development of gene expression-based score to predict sensitivity of multiple myeloma cells to DNA methylation inhibitorsJérôme Moreaux, Thierry Rème, Wim Leonard, et al.
Plos One|May 7, 2013
Inhibition of DEPDC1A, a bad prognostic marker in multiple myeloma, delays growth and induces mature plasma cell markers in malignant plasma cellsAlboukadel Kassambara, Matthieu Schoenhals, Jérôme Moreaux, et al.
Oncogene|April 24, 2002
Cooperation between heparin-binding EGF-like growth factor and interleukin-6 in promoting the growth of human myeloma cellsYue Dan Wang, John De Vos, Michel Jourdan, et al.
Blood|October 25, 2003
An inhibitor of the EGF receptor family blocks myeloma cell growth factor activity of HB-EGF and potentiates dexamethasone or anti-IL-6 antibody-induced apoptosisKarène Mahtouk, Michel Jourdan, John De Vos, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 12, 2011
Gene expression profiling in multiple myeloma--reporting of entities, risk, and targets in clinical routineTobias Meissner, Anja Seckinger, Thierry Rème, et al.
Journal of Hematology & Oncology|April 19, 2015
Insulin like growth factor binding protein 7 (IGFBP7) expression is linked to poor prognosis but may protect from bone disease in multiple myelomaArnold Bolomsky, Dirk Hose, Martin Schreder, et al.
Srpski Arhiv Za Celokupno Lekarstvo|February 23, 2012
The role of fluorescence in situ hybridization and gene expression profiling in myeloma risk stratificationDirk Hose, Anja Seckinger, Anna Jauch, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 23, 2008
Granulocyte-macrophage colony-stimulating factor potentiates rituximab in patients with relapsed follicular lymphoma: results of a phase II studyGuillaume Cartron, Lu Zhao-Yang, Marion Baudard, et al.
BMC Bioinformatics|January 15, 2008
A new method for class prediction based on signed-rank algorithms applied to Affymetrix microarray experimentsThierry Rème, Dirk Hose, John De Vos, et al.
Pageof 13

Showing results (41-50 of 121) with videos related to

Sort By:
Pageof 13
British Journal of Haematology|April 17, 2004
The Bcl-2 family member Bfl-1/A1 is strongly repressed in normal and malignant plasma cells but is a potent anti-apoptotic factor for myeloma cellsKarin Tarte, Michel Jourdan, Jean Luc Veyrune, et al.
Molecular Cancer Therapeutics|October 23, 2012
Development of gene expression-based score to predict sensitivity of multiple myeloma cells to DNA methylation inhibitorsJérôme Moreaux, Thierry Rème, Wim Leonard, et al.
Plos One|May 7, 2013
Inhibition of DEPDC1A, a bad prognostic marker in multiple myeloma, delays growth and induces mature plasma cell markers in malignant plasma cellsAlboukadel Kassambara, Matthieu Schoenhals, Jérôme Moreaux, et al.
Oncogene|April 24, 2002
Cooperation between heparin-binding EGF-like growth factor and interleukin-6 in promoting the growth of human myeloma cellsYue Dan Wang, John De Vos, Michel Jourdan, et al.
Blood|October 25, 2003
An inhibitor of the EGF receptor family blocks myeloma cell growth factor activity of HB-EGF and potentiates dexamethasone or anti-IL-6 antibody-induced apoptosisKarène Mahtouk, Michel Jourdan, John De Vos, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 12, 2011
Gene expression profiling in multiple myeloma--reporting of entities, risk, and targets in clinical routineTobias Meissner, Anja Seckinger, Thierry Rème, et al.
Journal of Hematology & Oncology|April 19, 2015
Insulin like growth factor binding protein 7 (IGFBP7) expression is linked to poor prognosis but may protect from bone disease in multiple myelomaArnold Bolomsky, Dirk Hose, Martin Schreder, et al.
Srpski Arhiv Za Celokupno Lekarstvo|February 23, 2012
The role of fluorescence in situ hybridization and gene expression profiling in myeloma risk stratificationDirk Hose, Anja Seckinger, Anna Jauch, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 23, 2008
Granulocyte-macrophage colony-stimulating factor potentiates rituximab in patients with relapsed follicular lymphoma: results of a phase II studyGuillaume Cartron, Lu Zhao-Yang, Marion Baudard, et al.
BMC Bioinformatics|January 15, 2008
A new method for class prediction based on signed-rank algorithms applied to Affymetrix microarray experimentsThierry Rème, Dirk Hose, John De Vos, et al.
Pageof 13